ClinicalTrials.gg
TerminatedNCT02299635Updated Jan 8, 2019Results posted

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

A Phase 2 interventional study of PF-03084014 and PF-03084014 in Triple Negative Breast Neoplasms, sponsored by Pfizer. Terminated at 37 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Triple Negative Breast Neoplasms by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Triple Negative Breast Neoplasms · Pfizer.

Enrollment
18th of 18
19 · median 122
Started
2015
with 1 other
Phase 2
2 of 18
none open now
Registered
8th of 18
by date

Among the 18 studies in Triple Negative Breast Neoplasms by Pfizer, this one is the 18th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 2, and was the 8th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

2 of the 18 studies in Triple Negative Breast Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Triple Negative Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • PF-03084014
  • Notch Alterations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of triple negative breast cancer (TNBC) with evidence of a) or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent.
  • Availability of an original diagnostic tumor tissue or the most recent metastatic tumor (archival biopsy or de novo biopsy) and a peripheral blood sample for Notch receptors genomic profiling

Exclusion criteria

Exclusion Criteria:

  • Known .
  • Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    PF-03084014

    PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.

    Drug: PF-03084014

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response (OR) Rate in Participants With Advanced Triple Receptor-Negative Breast Cancer (mTNBC) Harboring Activating Genomic Alterations in Notch Receptors (NA+)

    OR status based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis less than \[\<\]10 millimeter \[mm\]). PR: Greater than or equal to (\>=)30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.

    Time frame: Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.

Secondary outcomes

  1. OR Rate in Participants With mTNBC Whose Tumors Tested Negative for Eenomic Alterations in Notch Receptor (NA-)

    OR status based on assessment of confirmed CR or confirmed PR according to RECIST 1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis \<10 mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.

    Time frame: Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.

  2. Progression-Free Survival (PFS) in Participants With NA+ or NA mTNBC

    The period from study entry until disease progression, death, whichever occurred first as per RECIST version 1.1.

    Time frame: 2 years

  3. Duration of Response (DR) in Participants With NA+ or NA mTNBC

    Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. DR was calculated for the subgroup of patients with a confirmed objective tumor response. Objective Progression (PD): 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: 2 years

  4. One-Year Survival Probability in Participants With NA+ or NA mTNBC

    Overall survival (OS) status (alive or not) at 1 year after study entry. The the survival probability at 1 year was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.

    Time frame: 1 year

  5. Overall Survival (OS) in Participants With NA+ or NA mTNBC

    OS was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.

    Time frame: 2 years

  6. Type of Notch Genomic Alterations in Participants With NA+ mTNBC

    Type of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC

    Time frame: 2 years

  7. Pre-dose Serum Concentration (Ctrough) for PF-03084014

    Time frame: Day 1 of Cycle 1, 2, 3, and 5

  8. Pharmacodynamic (PD) Effects of PF-03084014 in Tumor Specimens and Peripheral Blood

    Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.

    Time frame: Day 1 of Cycle 1, 2, 3, and 5

  9. Alterations in Genes, Proteins, and RNAs Relevant to the Notch Signaling Pathway, to TNBC Biology, and to Sensitivity/Resistance to PF-03084014 in Tumor Specimens and Peripheral Blood.

    Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.

    Time frame: Day 1 of Cycle 1, 2, 3, and 5

  10. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as all deaths, regardless of cause, from treatment start until 28 days after the last dose and non-fatal events occurring after treatment start regardless of cause, up until 28 days after the last dose or until start of new anti-cancer treatment, whichever was first.

    Time frame: 2 years

  11. Number of Participants With Treatment-Emergent AEs by CTCAE Grade

    An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. AEs were defined according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: 2 years

  12. Number of Participants With Laboratory Test (Hematology) Abnormalities

    Number of participants with CTCAE version 4.03 grade 1 to 4 hematological test abnormalities.

    Time frame: Day 1 of Cycles 1, 2, 3, 4, 5, and subsequent cycles.

  13. Number of Participants With Laboratory Test (Chemistry) Abnormalities

    Number of participants with CTCAE version 4.03 grade 1 to 4 chemistry test abnormalities

    Time frame: Day 1 and Day 15 of Cycles 1, 2, 3, 4, 5, and subsequent cycles up to Cycle 8 and Day 8 of Cycle 1

  14. Number of Participants With Laboratory Test (Urinalysis) Abnormalities

    Number of participants with CTCAE version 4.03 grade 1 to 4 urinalysis test abnormalities for urine protein.

    Time frame: Day 1 of Cycle 1

  15. Number of Notch Genomic Alterations in Participants With NA+ mTNBC

    Number of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC

    Time frame: 2 years

07

Results

Posted Jan 13, 2017
Limitations and caveats
This study was terminated prematurely based on project re-prioritization by the Sponsor and was not due to any safety concerns or regulatory actions.

Participant flow

Participant flow — Overall Study
MilestonePF-03084014
Started19
Completed0
Not completed19
Withdrew: Adverse event2
Withdrew: Death1
Withdrew: Global deterioration of health status1
Withdrew: Objective progression or relapse10
Withdrew: Withdrawal by subject2
Withdrew: Other3

Outcome measures

PrimaryObjective Response (OR) Rate in Participants With Advanced Triple Receptor-Negative Breast Cancer (mTNBC) Harboring Activating Genomic Alterations in Notch Receptors (NA+)

OR status based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis less than \[\<\]10 millimeter \[mm\]). PR: Greater than or equal to (\>=)30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.

Time frame:
Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.

No measurements were reported for this outcome.

SecondaryOR Rate in Participants With mTNBC Whose Tumors Tested Negative for Eenomic Alterations in Notch Receptor (NA-)

OR status based on assessment of confirmed CR or confirmed PR according to RECIST 1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis \<10 mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.

Time frame:
Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) in Participants With NA+ or NA mTNBC

The period from study entry until disease progression, death, whichever occurred first as per RECIST version 1.1.

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryDuration of Response (DR) in Participants With NA+ or NA mTNBC

Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. DR was calculated for the subgroup of patients with a confirmed objective tumor response. Objective Progression (PD): 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryOne-Year Survival Probability in Participants With NA+ or NA mTNBC

Overall survival (OS) status (alive or not) at 1 year after study entry. The the survival probability at 1 year was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.

Time frame:
1 year

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) in Participants With NA+ or NA mTNBC

OS was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryType of Notch Genomic Alterations in Participants With NA+ mTNBC

Type of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryPre-dose Serum Concentration (Ctrough) for PF-03084014
Time frame:
Day 1 of Cycle 1, 2, 3, and 5

No measurements were reported for this outcome.

SecondaryPharmacodynamic (PD) Effects of PF-03084014 in Tumor Specimens and Peripheral Blood

Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.

Time frame:
Day 1 of Cycle 1, 2, 3, and 5

No measurements were reported for this outcome.

SecondaryAlterations in Genes, Proteins, and RNAs Relevant to the Notch Signaling Pathway, to TNBC Biology, and to Sensitivity/Resistance to PF-03084014 in Tumor Specimens and Peripheral Blood.

Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.

Time frame:
Day 1 of Cycle 1, 2, 3, and 5

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as all deaths, regardless of cause, from treatment start until 28 days after the last dose and non-fatal events occurring after treatment start regardless of cause, up until 28 days after the last dose or until start of new anti-cancer treatment, whichever was first.

Time frame:
2 years
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsPF-03084014
Number of Participants with AEs18
Number of Participants with SAEs6
SecondaryNumber of Participants With Treatment-Emergent AEs by CTCAE Grade

An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. AEs were defined according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
2 years
Reported as:
Number · participants
Number of Participants With Treatment-Emergent AEs by CTCAE Grade
participantsPF-03084014
Any AEs, Grade 11
Any AEs, Grade 25
Any AEs, Grade 39
Any AEs, Grade 41
Any AEs, Grade 52
SecondaryNumber of Participants With Laboratory Test (Hematology) Abnormalities

Number of participants with CTCAE version 4.03 grade 1 to 4 hematological test abnormalities.

Time frame:
Day 1 of Cycles 1, 2, 3, 4, 5, and subsequent cycles.
Reported as:
Number · participants
Number of Participants With Laboratory Test (Hematology) Abnormalities
participantsPF-03084014
Anemia12
Lymphocyte count increased0
Lymphopenia11
Neutrophils (absolute)0
Platelets3
White blood cells4
SecondaryNumber of Participants With Laboratory Test (Chemistry) Abnormalities

Number of participants with CTCAE version 4.03 grade 1 to 4 chemistry test abnormalities

Time frame:
Day 1 and Day 15 of Cycles 1, 2, 3, 4, 5, and subsequent cycles up to Cycle 8 and Day 8 of Cycle 1
Reported as:
Number · participants
Number of Participants With Laboratory Test (Chemistry) Abnormalities
participantsPF-03084014
Alanine aminotransferase5
Alkaline phosphatase6
Aspartate aminotransferase9
Bilirubin (total)1
Creatine kinase1
Creatinine13
Gamma glutamyl transferase1
Hypercalcemia3
Hyperglycemia13
Hyperkalemia3
Hypermagnesemia1
Hypernatremia0
Hypoalbuminemia8
Hypocalcemia4
Hypoglycemia1
Hypokalemia5
Hypomagnesemia3
Hyponatremia6
Hypophosphatemia14
SecondaryNumber of Participants With Laboratory Test (Urinalysis) Abnormalities

Number of participants with CTCAE version 4.03 grade 1 to 4 urinalysis test abnormalities for urine protein.

Time frame:
Day 1 of Cycle 1
Reported as:
Number · participants
Number of Participants With Laboratory Test (Urinalysis) Abnormalities
participantsPF-03084014
Number of Participants With Laboratory Test (Urinalysis) Abnormalities2
SecondaryNumber of Notch Genomic Alterations in Participants With NA+ mTNBC

Number of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC

Time frame:
2 years

No measurements were reported for this outcome.

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-03084014—6/19 (31.6%)18/19 (94.7%)
Most frequent serious events
Most frequent serious events
EventPF-03084014
Confusional statePsychiatric disorders2/19
Disease progressionGeneral disorders1/19
PyrexiaGeneral disorders1/19
Lung infectionInfections and infestations1/19
HypophosphataemiaMetabolism and nutrition disorders1/19
Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/19
DyspnoeaRespiratory, thoracic and mediastinal disorders1/19
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPF-03084014
DiarrhoeaGastrointestinal disorders11/19
NauseaGastrointestinal disorders8/19
FatigueGeneral disorders8/19
VomitingGastrointestinal disorders7/19
HypophosphataemiaMetabolism and nutrition disorders7/19
PyrexiaGeneral disorders5/19
CoughRespiratory, thoracic and mediastinal disorders5/19
DyspepsiaGastrointestinal disorders3/19
Mucosal inflammationGeneral disorders3/19
ConjunctivitisInfections and infestations3/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)PF-03084014
Mean57.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PF-03084014
Female19
Male0
08

Study locations

37 sites
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305, United States
  • Stanford Women's Cancer Center
    Stanford, California 94305, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
  • Midwestern Regional Medical Center
    Zion, Illinois 60099, United States
  • Brigham and Women's Hospital (BWH)
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute (DFCI)
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • The Valley Hospital - Luckow Pavilion
    Paramus, New Jersey 07652, United States
  • Valley Medical Group
    Paramus, New Jersey 07652, United States
  • Valley Medical Group
    Westwood, New Jersey 07675, United States
  • Memorial Sloan Kettering Cancer Center Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center West Harrison
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center Rockville Centre
    Rockville Centre, New York 11570, United States
  • Memorial Sloan Kettering Cancer Center Sleepy Hollow
    Sleepy Hollow, New York 10591, United States
  • Debreceni Egyetem, Klinikai Kozpont, Onkologiai Intezet
    Debrecen, 4032, Hungary
  • Presidio Ospedaliero Vito Fazzi
    Lecce, 73100, Italy
  • Istitutio Europeo di Oncologia
    Milan, 20141, Italy
  • Vesalius
    Krakow, 31108, Poland
  • Vesalius Poradnia Onkologiczna i Hematologiczna
    Krakow, 31216, Poland
  • Szpital Kliniczny Przemienienia Panskiego, Uniwersutetu Medycznego im. Karola Marcinkowskiego
    Poznan, 60-569, Poland
  • Complejo Hospitalario Universitario A Coruna (Hospital Teresa Herrera)
    A Coruna, 15006, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Instituto Catalan de Oncologia de L'Hospitalet de Llobregat (ICO)
    Barcelona, 08908, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Beatson West of Scotland Cancer Centre
    Glasgow, Scotland G12 0YN, United Kingdom
  • Ross Hall Hospital
    Glasgow, Scotland G52 3NQ, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Surrey, SM2 5PT, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Jan 2016, 11 months.

Results were first posted in Jan 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 24, 2014
StartActual
Feb 3, 2015
Primary completionActual
Jan 14, 2016
CompletionActual
Jan 14, 2016
Results first posted
Jan 13, 2017
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02299635
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
Feb 3, 2015
Primary completion
Jan 14, 2016
Completion
Jan 14, 2016
Results posted
Jan 13, 2017
Last update
Jan 8, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion